Andy Stergachis is a Professor of Pharmacy and Global Health and Adjunct Professor of Health Metrics Sciences, Epidemiology and Health Services. He is Associate Dean for Research and Graduate Programs in the School of Pharmacy, Director of the Global Medicines Program and Director of the Biomedical Regulatory Affairs Program. He is a co-investigator with IHME’s Global Research on Antimicrobial Resistance (GRAM) Project that is estimating the magnitude and trends in the global burden of antimicrobial resistance. He works with the USAID-funded Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program and the Bill & Melinda Gates Foundation-funded landscape analysis on sentinel site readiness for maternal immunization active safety surveillance in LMICs. He is co-investigator with the NIH-funded Washington Entrepreneurial Research Evaluation and Commercialization Hub, established to accelerate the transformation of health research innovation into market ready products and services that impact health outcomes. He is co-investigator of a project to develop and evaluate a community pharmacy-based population health intervention for people living with epilepsy in the U.S. He has a special interest in the validation and use of large linked databases and innovative methods for safety surveillance of drugs and vaccines in LMICs and in strengthening the evidence-base for pharmacy services aimed at improving health and economic outcomes.
Dr. Stergachis earned his Bachelors in Pharmacy degree from Washington State University and his MS and PhD from the University of Minnesota. He completed a postdoctoral fellowship in health services research at the St. Louis Park Medical Center, Minneapolis, MN. He is an elected member of the National Academy of Medicine and a Fellow of the American Pharmacists Association and of the International Society for Pharmacoepidemiology.
IHME was established at the University of Washington in Seattle in 2007. Its mission is to improve health through better health evidence.